OBJECTIVES To assess symptoms, functionality, quality of life (QoL), and work/ productivity loss in Rheumatoid Arthritis (RA) patients treated with subcutaneous (SC) biologics. METHODS Patient-reported data from the 2007 Rheumatoid Arthritis Patient Study were analyzed. Symptoms were measured by morning stiffness, fatigue, and pain scores defined on a scale from 0 (no symptom) to 10 (severe symptom). The Health Assessment Questionnaire (HAQ) was used to measure functional status (scores 0-3). QoL was measured by the mental (MCS) and physical (PCS) component summary scores of the Short Form-8 (SF-8). Work/productivity loss was measured by the Work Productivity and Activity Impairment (WPAI) instrument. Comparisons were made between patients who currently use SC biologics versus those who discontinued treatment. RESULTS Of the 2,200 survey respondents (72% female; average age =49.6years), 386 (17.5%) used SC biologics. The average duration of RA was 12.4 years, with 14% reporting severe disease. The patient-reported mean scores were: morning stiffness 6.6, fatigue 6.8, pain 6.5, HAQ 1.6, MCS 43.9 and PCS 36.4. Patients reported 61.0% work impairment and 59.2% impairments in daily activity. Patients who had discontinued SC biologic therapy (N=124, 32.1%) reported significantly worse scores in morning stiffness, fatigue, pain, and PCS (all P<0.05) versus patients currently treated with SC biologics (N=262, 67.9%). Patients who discontinued therapy had more work/activity loss; only activity impairment was statistically significant (P<0.05). There was no significant difference in HAQ scores between groups. CONCLUSIONS RA patients using current SC biologics still suffer from serious impairments in symptoms, functional status, QoL, and work/productivity. However, patients who discontinued SC biologic therapy have significantly worse symptom scores, physical functioning, and activity impairment compared with those currently being treated. Both findings indicate there is still an unmet medical need in RA patients.